Metother (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This inhibition reduces the proliferation of rapidly dividing cells, including immune cells involved in inflammation and malignant cells in cancer.

The dose of Metother is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. No fixed regimen is provided here; the prescriber determines the appropriate dosing schedule.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated during pregnancy and should not be used by breastfeeding mothers, as it can be excreted in breast milk and harm the infant.

To order Metother, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

For rheumatoid arthritis, methotrexate (Metother) is often compared with leflunomide or biologic agents such as TNF‑α inhibitors. Methotrexate is a small‑molecule immunosuppressant with a well‑established efficacy‑safety profile, whereas biologics target specific cytokines and may have higher costs and different infection risks.

Metother should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid freezing. Follow standard aseptic techniques when preparing the subcutaneous injection.

Metother is supplied for subcutaneous injection. A healthcare professional or trained individual administers the dose into the subcutaneous tissue, typically in the abdomen, thigh or upper arm, following aseptic technique and the prescriber's instructions.

Serious risks include severe liver toxicity, interstitial pneumonitis or pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and acute renal failure. Patients should be monitored regularly for liver enzymes, lung symptoms, blood counts and renal function.

Metother is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe renal or hepatic impairment, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing blood dyscrasias.